Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 13/20 | 0.75 |
| ▸ | PDGFRA | P16234 | 11/20 | 0.70 |
| ▸ | KIT | P10721 | 6/20 | 0.70 |
| ▸ | KDR | P35968 | 3/20 | 0.70 |
| ▸ | BCR | P11274 | 6/20 | 0.67 |
| ▸ | LYN | P07948 | 1/20 | 0.67 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.66 |
| ▸ | EGFR | P00533 | 1/20 | 0.64 |
| ▸ | PRKCA | P17252 | 1/20 | 0.64 |
| ▸ | BRAF | P15056 | 1/20 | 0.62 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1654084 | 0.97 | PDGFRA (0.71) | ABL1PDGFRAKITKDRBCR | |
| SCHEMBL3530749 | 0.91 | ABL1 (0.74) | ABL1PDGFRAKITKDRBCR | |
| SCHEMBL3536285 | 0.89 | ABL1 (0.76) | ABL1PDGFRAKITKDRBCR | |
| SCHEMBL11927833 | 0.88 | PDGFRA (0.68) | ABL1PDGFRAKITKDRBCR | |
| SCHEMBL1654178 | 0.88 | PDGFRA (0.70) | ABL1PDGFRAKITKDRBCR | |
| SCHEMBL3532229 | 0.88 | ABL1 (0.76) | ABL1PDGFRAKITKDRBCR | |
| SCHEMBL27549071 | 0.87 | PDGFRA (0.74) | ABL1PDGFRAKITKDRBCR | |
| SCHEMBL3526105 | 0.87 | ABL1 (0.75) | ABL1PDGFRAKITKDRBCR | |
| SCHEMBL3530581 | 0.86 | ABL1 (0.74) | ABL1PDGFRAKITKDRBCR | |
| SCHEMBL3528980 | 0.86 | ABL1 (0.79) | ABL1PDGFRAKITKDRBCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655669-B2 | Pyrimidineamide derivatives and the use thereof | NOVARTIS AG (CH) | 2010-02-02 | — | — | US | disclosed |
| US-20060142577-A1 | Novel pyrimidineamide derivatives and the use thereof | NOVARTIS AG (CH) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142577-A1 | Novel pyrimidineamide derivatives and the use thereof | TYMP, NME2, DPYD | ABL1 197/4885PDGFRA 366/4885KIT 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.